Opus Genetics (IRD) CEO sells 9,511 shares to cover tax withholding

Rhea-AI Filing Summary

Opus Genetics, Inc. Chief Executive Officer George Magrath reported an automatic disposition of common stock tied to a tax event. On April 23, 2026, 9,511 shares of common stock were sold at $5.22 per share to satisfy tax withholding obligations from a restricted stock unit vesting and settlement. According to the filing, this did not represent a discretionary trade by the executive. After this transaction, Magrath directly holds 1,741,344 shares of Opus Genetics common stock.

Insights

Equity compensation analyst

CEO’s 9,511-share sale is a routine tax-withholding event, not a discretionary stock trade.

The filing shows CEO George Magrath had 9,511 Opus Genetics common shares sold at $5.22 per share. A footnote explains the sale was automatically executed to cover tax withholding from a restricted stock unit vesting and settlement.

This kind of transaction is common in equity compensation programs and usually carries limited signaling value about management’s view of the stock. After the sale, Magrath still directly owns 1,741,344 shares, so the disposition is small relative to his overall position.

Insider Trade Summary

Net Seller: 9,511 shares

Net Sell 1 txn

Insider Magrath George

Role Chief Executive Officer

Sold 9,511 shs ($50K)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,511	$5.22	$50K

Holdings After Transaction: Common Stock — 1,741,344 shares (Direct)

Footnotes (1)

1. F1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

Key Figures

Shares sold: 9,511 shares Sale price: $5.22 per share Shares held after transaction: 1,741,344 shares +1 more

4 metrics

Shares sold 9,511 shares Automatic tax-withholding sale on April 23, 2026

Sale price $5.22 per share Price for 9,511 Opus Genetics common shares

Shares held after transaction 1,741,344 shares CEO George Magrath’s direct holdings post-transaction

Net shares sold 9,511 shares Net-sell direction per transaction summary

Key Terms

restricted stock units, tax withholding obligations, open-market sale, non-derivative

4 terms

restricted stock units financial

"a vesting and settlement event from a restricted stock units award"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold automatically ... to satisfy tax withholding obligations that arose"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

""transaction_type": "non-derivative""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 04/27/2026 - 04:27 PM Learn about SEC filing dates

FAQ

What did Opus Genetics (IRD) CEO George Magrath report in this Form 4?

Opus Genetics CEO George Magrath reported an automatic sale of 9,511 common shares at $5.22 per share. The sale covered tax withholding from a restricted stock unit vesting, and he continues to directly own 1,741,344 Opus Genetics shares afterward.

Was the Opus Genetics (IRD) CEO’s 9,511-share sale a discretionary trade?

No, the filing states the 9,511 shares were sold automatically to satisfy tax withholding obligations from a restricted stock unit vesting. The footnote clarifies this transaction did not represent a discretionary trade or independent trading decision by CEO George Magrath.

How large is George Magrath’s remaining Opus Genetics (IRD) stake after this sale?

After the automatic tax-related sale, CEO George Magrath directly holds 1,741,344 Opus Genetics common shares. This indicates the 9,511 shares sold for tax withholding represent a relatively small portion of his overall direct equity position in the company.

What was the price per share in the Opus Genetics (IRD) CEO’s reported sale?

The reported transaction shows 9,511 Opus Genetics common shares sold at $5.22 per share. The filing describes this as an automatic sale conducted to cover tax withholding obligations related to a restricted stock unit vesting and settlement event.

What triggered the tax withholding sale reported for Opus Genetics (IRD) CEO?

The tax withholding sale was triggered by a vesting and settlement event from a restricted stock unit award. To cover associated tax obligations, 9,511 shares of Opus Genetics common stock were automatically sold on behalf of CEO George Magrath at $5.22 per share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Magrath George

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/23/2026		S(1)		9,511	D	$5.22	1,741,344	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

	/s/ Amy Rabourn, by Power of Attorney	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)